Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disorder ofunknown etiology. SLE mostly effects women of childbearing age and varies in mild to life- threatening manifestations. Immune dysregulation results in autoantibodies productionsubsequently inciting multiorgan damage involving the central nervous system, kidneys, musculoskeletal, and the skin. Current conventional therapy mitigate prognosis of diagnosed SLE patients, however the occurrence of refractory SLE and the damaging side effects of conventional therapy indicate improved alternative targeted therapy. Novel therapeutic proposals targeting the pathogenic pathways of SLE have been developed, targeting B-cells, T-cells, and cytokine production.